Are serum biomarkers useful in the management of systemic sclerosis-associated interstitial lung disease?

Respirology. 2021 May;26(5):406-408. doi: 10.1111/resp.14017. Epub 2021 Feb 20.

Authors

Susanna M Proudman^{1

2}, Tamera J Corte^{3

4}

Affiliations

¹ Discipline of Medicine, University of Adelaide, Adelaide, SA, Australia.
² Rheumatology Unit, Royal Adelaide Hospital, Adelaide, SA, Australia.
³ Centre of Research Excellence for Pulmonary Fibrosis, University of Sydney, Sydney, NSW, Australia.
⁴ Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia.

PMID: 33611844
DOI: 10.1111/resp.14017

No abstract available

Keywords: biomarker; disease progression; interstitial lung disease, systemic sclerosis.

Publication types

Editorial
Comment

MeSH terms

Biomarkers
Humans
Lung Diseases, Interstitial* / diagnosis
Lung Diseases, Interstitial* / etiology
Lung Diseases, Interstitial* / therapy
Scleroderma, Systemic* / complications

Substances

Biomarkers